---
title: MRD-directed and risk-adapted individualized stratified treatment of AML
date: '2023-11-16'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37969959/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20231117170645&v=2.17.9.post6+86293ac
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Measurable residual disease (MRD) has been widely recognized as a biomarker
  for deeply evaluating complete remission (CR), predicting relapse, guiding pre-emptive
  interventions, and serving as an endpoint surrogate for drug testing. However, despite
  the emergence of new technologies, there remains a lack of comprehensive understanding
  regarding the proper techniques, sample materials, and optimal time points for MRD
  assessment. In this review, we summarized the MRD methods, sample sources, ...
disable_comments: true
---
Measurable residual disease (MRD) has been widely recognized as a biomarker for deeply evaluating complete remission (CR), predicting relapse, guiding pre-emptive interventions, and serving as an endpoint surrogate for drug testing. However, despite the emergence of new technologies, there remains a lack of comprehensive understanding regarding the proper techniques, sample materials, and optimal time points for MRD assessment. In this review, we summarized the MRD methods, sample sources, ...